Faculty of the Fourth International Patient & Physician Summit on Waldenström's Macroglobulinemia
Select from the list below to view a biography of the selected faculty member.
Irene Ghobrial is an Assistant Professor at Harvard Medical School. She received her MD in 1995 from Cairo University. She completed her residency in internal medicine at Wayne State University, Sinai-Grace Hospital in Detroit, Michigan, and her hematology/oncology fellowship at the Mayo Clinic in Rochester, Minnesota. She joined DFCI in October, 2005. Here, her basic science and clinical work focuses on the development of novel therapeutic agents for the treatment of Waldenstrom’s and multiple myeloma, with particular interest in the PI3K/AKT/mTOR pathway. She also has a special interest in the role of chemokine receptor CXCR4 in the migration and homing of multiple myeloma and Waldenström’s. Dr. Ghobrial is the recipient of the American Society of Hematology Scholar Award, the American Society of Clinical Oncology Foundation Young Investigator Award, and a Smokler Award from the Research Fund for Waldenstrom Foundation. She is also a Leukemia and Lymphoma Society scholar and a Lymphoma Research Foundation scholar.
Currently, Dr. Ghobrial oversees the Kirsch Laboratory for Waldenstrom's, a lab within the Bing Center for Waldenstrom's macroglobulinemia.
Stephanie Gregory holds the Elodia Kehm Chair of Hematology and is Professor of Medicine and Director of the Section of Hematology at Rush University Medical Center/Rush University, Chicago, Illinois. Dr. Gregory received her medical degree with honors from The Woman’s Medical College of Pennsylvania in Philadelphia, Pennsylvania. Her postgraduate training included an internship, residency and chief residency in internal medicine at Rush University Medical Center. She then underwent three years of subspecialty training in hematology with a research grant from the Schweppe Foundation. This was also at Rush University Medical Center. She is certified by the American Board of Internal Medicine and holds subspecialty certification in hematology.
Dr. Gregory’s career has been directed toward patient care, teaching, research and administration. She was elected to the “Mark H. Lepper, M.D. Society of Teachers” at Rush Medical College in 1986. She received an endowed chair as Director of Hematology at Rush in 1995. She was elected the first woman president of the Chicago Society of Internal Medicine from 1994 to 1995. She is a Fellow of the American College of Physicians, a member of the Northern Illinois Council of the College, and in 1996 received the “Illinois Laureate Award” from the College. She was awarded the “1998 Alumnae Achievement Award” by the Medical College of Pennsylvania/Hahnemann Medical School. She received the “Excellence in Medicine Award” from the Department of Medicine of Rush University Medical Center in 2006. In 2008 Dr. Gregory was awarded the Lymphoma Research Foundation’s “Chicago HOPE Award.”
In 1992, Dr. Gregory did medical missionary work in Haiti and in 1994 was selected to go to Croatia as a member of the “United Nations Security Council Commission of Experts Investigating War Crimes and Sexual Assaults Against Women in the Former Yugoslavia.”
Her research interests include Hodgkin and non-Hodgkin lymphomas, leukemias and myelomas, especially using novel approaches of immunotherapy. Dr. Gregory has been involved in several radioimmunotherapy trials in non-Hodgkin lymphoma and is presently involved in many clinical trials with small molecules targeted to malignant lymphoma and leukemia cells. She has chaired or co-chaired several national and international symposia on hematologic malignancies. In September 2008, she was co-chair of the “American Society of Hematology State-of-the-Art Symposium.” She is the senior author of the fourth edition of the “American Society of Hematology Self-Assessment Program Book (ASH-SAP).” She has authored or coauthored 458 manuscripts, books, book chapters and abstracts. Dr Gregory speaks extensively on hematologic malignancies both nationally and internationally.
Dr. Gregory is Vice Chair of the Medical Affairs Board of the Lymphoma Research Foundation and a member of the Advisory Boards of the Leukemia Research Foundation and the Leukemia/Lymphoma Society of America. She is an active member of the American Society of Hematology, American Society of Clinical Oncology and numerous other medical professional associations.
Dr. Hochberg's interests include Brain Lymphoma, gene therapy for glioma and the use of phase 1 and phase 2 agents to treat glioblastoma. He is the P.I. of an NCI-PO1 (Gene Therapy for Brain Tumors) which explores novel herpes vector systems expressing pro-drug activating transgenes. In addition he has been the PI of an NCI Consortium award to the Massachusetts General Hospital for the study of novel therapies of malignant brain tumors. Current research activities include the evaluation of risk factors for the development and progression of brain lymphoma including analyses of subtle alterations of cell-mediated immunity that might predispose to tumor development in "immunocompetent" individuals, the role of IgH rearrangement, the role of sustained EBViral infections (E. Kieff). Translational trials include therapies employing novel viral vectors (herpes, Adenoviral) expressing tk and interferon transgenes; novel phase 1 agents including camptothecins, antifols and angiogenesis inhibitors. These trials make use of novel surrogates of drug delivery including microdialysis probes and imaging of tumor blood flow, blood volume and permeability.
Zachary Hunter has been with the Bing Center for over five years and has worked on multiple organizational and scientific projects during that time. His current research involves characterizing the role of IgG and IgA deficiency in Waldenstom’s Marcoglobulinemia as well as a large study examining the characteristics and genetics of families with a history of WM and other B-cell disorders. He holds a BA in mathematics from Haverford College and is a graduate student at the Boston University department of pathology. He is doing his thesis research with the Bing Center under Drs. Steven Treon of Dana-Farber and Christopher Andry of Boston University.
Ioakimidis joined the Bing Center for WM at Dana Farber Cancer Institute in late January 2007. Thea graduated with a Masters in Science from Metropolitan University in London with a focus in pharmaceutical Science and a thesis in computational chemistry. Her undergraduate degree was received from Northeastern University with a BS in biology. Thea is currently working on a familial study that will help us to gain knowledge about the genetics of this disease and will bring us closer to understanding of the cause of Waldenstrom’s Macroglobulinemia.
Dr. Kyle is Professor of Medicine, Laboratory Medicine and Pathology at Mayo Clinic College of Medicine in Rochester, Minnesota. After earning a medical degree with distinction at Northwestern University Medical School in Chicago, Dr. Kyle did residency training in internal medicine at the Mayo Clinic. He completed a research fellowship in hematology at Tufts University School of Medicine in Boston with Dr. William Dameshek, and a postdoctoral research fellowship from the National Cancer Institute. Dr. Kyle is Chairman of the Scientific Advisory Board and on the Board of Directors of the International Myeloma Foundation, and is Chairman of the Scientific Advisory Committee of the International Waldenström’s Macroglobulinemia Foundation (IWMF). He has been President of the International Society of Amyloidosis and is currently President of the International Myeloma Society. He is a Master, American College of Physicians, and an honorary member of the Royal Society of Pathologists, London. Dr. Kyle sits on the editorial boards of several journals, including Blood Reviews, Clinical Lymphoma & Myeloma, and Leukemia. Dr. Kyle has been principal investigator for numerous research studies. He was Chairman of the Myeloma Committee of the Eastern Cooperative Oncology Group for 12 years and been Secretary-General of the International Society of Hematology. He has served as Section Head and Chairman of the Division of Hematology at the Mayo Clinic. Among his contributions to medicine, Dr. Kyle coined the term monoclonal gammopathy of undetermined significance in 1978. He also coined the term smoldering multiple myeloma in 1980. He described the syndrome of idiopathic Bence Jones proteinuria. He was the first to publish prospective randomized studies on the treatment of amyloidosis. He is recognized for landmark contributions on the epidemiology of monoclonal gammopathy of undetermined significance. With research interests in monoclonal gammopathies, multiple myeloma, macroglobulinemia and amyloidosis, Dr. Kyle lectures widely and has contributed more than 850 articles and book chapters as well as over 1100 abstracts to the literature. He has been co-editor of five editions of Neoplastic Diseases of the Blood and co-editor of three editions of Myeloma, Biology and Management. Dr. Kyle was the first recipient of the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation and the Robert A. Kyle Award from the IWMF, and received the Mayo Clinic’s Henry S. Plummer Distinguished Internist Award, and the Distinguished Alumni Award. He has received honorary degrees from Polacky University, Olumouc, Czech Republic and the University of North Dakota. He was also the recipient of the David A. Karnofsky Award and Lecture from the American Society of Clinical Oncology in 2007 and the Wallace Coulter Award from the American Society of Hematology in 2008.
Dr Charalampia Kyriakou obtained her medical degree from the Aristotelion University of Thessaloniki, Greece and subsequently trained in haemato-oncology in the transplant unit at George Papanikolaou Hospital. She moved to University College London Hospital in London in 1997 where she completed a transplant followed by myeloma clinical fellowship. From 2002 to 2005 she was awarded the myeloma research fellowship and received her doctorate in mesenchymal stem cell research from Royal Free and University College London Medical School. Her basic research interest is focused on mesenchymal stem cell homing, gene transduction with anti-tumour genes and effect in in vivo lymphoma and myeloma mouse animal model together with in vitro interactions with lymphoma and myeloma cells. She is a member of the American Society of Hematology and Clinical Oncology. She is active member of the EBMT Lymphoma working party and her clinical interest is on transplantation for lymphoma and myeloma. She is currently the Lymphoma and Myeloma Lead at the North West London Hospital NHS Trust.
Dr. Landgren is a clinical investigator and Attending Physician at the Medical Oncology Branch, National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Landgren received his M.D. in 1995 from the Karolinska Institute (Stockholm, Sweden). Following clinical training as a hematology/internal medicine specialist physician and receipt of a Ph.D. at Karolinska Institute in Sweden, he designed and led clinical research on lymphoproliferative malignancies and related precursors. In 2004, he joined the NCI/NIH.
Dr. Landgren is a world leading physician-scientists with a strong research focus on monoclonal gammopathy of undetermined significance (MGUS) and its relation to full-blown malignancies including multiple myeloma, Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia. Dr. Landgren has designed and led several landmark studies focusing on MGUS and progression patterns into multiple myeloma. In the first prospective study, he has shown that all myeloma patients are preceded by a MGUS stage. Based on racial disparity patterns for MGUS and multiple myeloma among African-Americans and whites, as well as familial aggregation patterns for MGUS and multiple myeloma in Scandinavia, he has provided novel insights supporting a role for genetic and immune-related factors in myelomagenesis. Also he has led the first large African study on MGUS in Ghana. Further, he has designed and led the first prospective study showing that almost all chronic lymphocytic leukemia patients evolve through a precursor state (monoclonal B-cell lymphocytosis).
Dr. Landgren is leading the clinical plasma-cell disease program at the NCI/NIH, with particular focus on MGUS and multiple myeloma. He has an extensive publication track-record in leading peer-reviewed journals such as the New England Journal of Medicine, JAMA, Blood, Journal of Clinical Oncology, Journal of the National Cancer Institute, Archives of Internal Medicine, British Journal of Haematology, and Haematologica.
Dr. Mary McMaster received her B.A. in English from the University of North Carolina (UNC) and her M.D. from the Wake Forest University Bowman Gray School of Medicine. She then completed training in Internal Medicine and Medical Oncology at Vanderbilt University Medical Center. During her fellowship, she became interested in cancer genetics. While at Vanderbilt, she began to study the genetics of lymphoma. She returned to North Carolina for postdoctoral training in cellular biology and genetics. She joined the National Institutes of Health in 1996. She completed a residency in Clinical Medical Genetics with the National Human Genome Research Institute before moving to the National Cancer Institute (NCI) in 1998. At NCI, she has pursued her long-term interest in cancer genetics. She is especially interested in understanding the basis for susceptibility to certain rare cancers, including Waldenström’s macroglobulinemia (WM) and related blood and lymph node cancers. She began the first national registry for familial WM and worked closely with Dr. Arnold Smokler, who founded the International Waldenström’s Macroglobulinemia Foundation. Under her direction, the registry has grown from 3 families in 1998 to nearly 100 families as of December, 2008. She was a founding member of The International Waldenström’s Macroglobulinemia Workshop. The primary goal of her research is to understand why WM sometimes occurs in multiple members of a single family. In particular, she hopes to identify genetic and/or environmental factors that may cause a person to be susceptible to WM. To achieve that goal, her studies have several components. For example, she is interested in learning whether relatives of WM patients may have features or conditions besides WM. She is also exploring potential links between environmental exposures and WM. The answers to these questions may eventually help researchers to develop better ways to diagnose, treat, and ultimately prevent WM. In her studies of WM families, she provides clinical consultation and genetic counseling for WM patients, their relatives, and caregivers.
Dr. Merlini is the Director of the Amyloidosis Research and Treatment Center, Scientific Institute Policlinico San Matteo, University of Pavia, Italy. He established and now coordinates the Italian Amyloidosis network. He was trained in clinical and laboratory investigation of monoclonal gammapathies in the Centers directed by Prof. Jan Waldenström (Lund University, Sweden) and by Prof. Elliott Osserman (Columbia University, NY). His main research interests are the molecular mechanisms, natural history and treatment of monoclonal gammapathies and of systemic AL amyloidosis. He is the past President of the International Society of Amyloidosis.
Dr. Merlini attended the Medical School of the University of Pavia as an alumnus of the Ghislieri College. After being awarded his medical degree, he trained in clinical and laboratory investigation of monoclonal gammapathies at Malmö General Hospital, Lund University, Sweden under the close guidance of Prof. Jan Waldenström. The encounter with Prof. Waldenström left a permanent imprint in Dr. Merlini’s scientific interests which have been focused since then on the investigation of the molecular mechanisms of diseases, and in particular on the biological activities of monoclonal proteins, and of the related clinical conditions. He further developed these lines of research at the Institute of Cancer Research, College of Physicians & Surgeons, Columbia University, New York under the expert direction of Prof. Elliott Osserman and in collaboration with the immunochemist Prof. Elvin Kabat. Prof. Osserman introduced him to the realm of systemic amyloidosis, and particularly to amyloidosis caused by misfolded monoclonal immunoglobulin light chains.
Dr. Merlini’s main research interests are the pathogenesis, natural history, diagnosis and treatment of monoclonal gammapathies, in particular immunoglobulin light chain amyloidosis. Recently his research has focused on the investigation of biomarkers for assessing prognosis and response to therapy and on the development of novel therapeutic agents and treatment designed in the light of advances in the understanding of the molecular mechanisms of these diseases. He is, and has been, principal investigator for several research projects in this field funded by the European Community and national research agencies. Dr. Merlini lectures widely and has written more than 300 articles, books, book chapters and reviews. Dr. Merlini’s contribution to the field of Waldenström’s macroglobulinemia spans from the investigation of the antibody activities of the monoclonal IgMs to the definition of the prognosis and treatment guidelines, and development of new therapeutic avenues. He was instrumental in establishing an international collaboration to define a new prognostic scoring system for Waldenström s macroglobulinemia.
Dr. Enrica Morra is Head of the Division of Hematology (1994 - present) and Director of the Oncology Department (2001-present) at the Niguarda Ca’ Granda Hospital of Milan, Italy.
She received her medical degree from the University of Pavia Medical School and is board-certified in Haematology and Medical Oncology. Dr. Morra is a teacher at the Postgraduate School of Hematology at the Universities of Milan and Pavia. She has lectured at numerous international conferences and has organised several continuing medical education courses on hematologic malignancies. Her main research interests are the biological and therapeutical aspects of acute and chronic leukemias, monoclonal gammopathies, myeloproliferative disorders, myelodysplasia.
Dr. Morra is a member of the American Society of Hematology (ASH) and the European Hematology Association (EHA), and currently serves as regional delegate of the Italian Society of Hematology (SIE). She is the Scientific Coordinator of the Hematology Network of the Region Lombardia, which includes all hematology centres of this area. Dr Morra has authored or co-authored 190 papers in peer-reviewed journals.
Owen A. O’Connor, M.D., Ph.D., Associate Professor of Medicine, is the Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University, and Chief of the Lymphoma Service in the College of Physicians and Surgeons at The New York Presbyterian Hospital at Columbia University. His clinical and research interests focus on the discovery and development of novel small molecules for the treatment of hematologic malignancies.
Dr. O’Connor received his Ph.D. from the New York University School of Medicine in Biochemical Toxicology and Chemical Carcinogenesis, and his M.D. from the University of Medicine and Dentistry of New Jersey. He then went on to complete a medical internship and residency at The New York Hospital-Cornell University Medical Center. Following his medical residency, he completed a fellowship in Medical Oncology at the Memorial Sloan Kettering Cancer Center, where he was Chief Fellow from 1997-1998, and a Fellowship in Clinical Pharmacology at the New York Hospital-Cornell University Medical School. During his fellowship, he worked in the laboratory of Dr. Joseph R. Bertino studying mechanisms of drug resistance. Prior to joining the faculty at Columbia University, we was an Attending Physician in the Department of Medicine on the Lymphoma Service, and Head of the Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies at Memorial Sloan Kettering Cancer Center. Dr. O’Connor maintains a laboratory program focused on the discovery of novel small molecules for the treatment of non-Hodgkin's lymphoma and Hodgkin Lymphoma using unique animal models of these diseases and high-throughput screening approaches. Clinically, he is focused on the conduct of Phase I and II clinical trials, with an emphasis on pharmacokinetic and pharmacodynamic studies. He has a particular interest in the development of proteasome inhibitors, epigenetic therapies and Bcl-2 targeted drugs for the treatment of lymphoproliferative malignancies. To date, his efforts in conducting early phase clinical trials with bortezomib (Velcade) and SAHA (Vorinostat) have led to recent FDA approvals of these drugs for the treatment of mantle cell and cutaneous T-cell lymphoma. He is now the PI of an international registration directed trial of pralatrexate in T-cell lymphoma, a drug he co-discovered and developed.
Dr. O’Connor is a member of several professional societies, including the American Association for Cancer Research, the American Society for Clinical Oncology, the American Society of Clinical Pharmacology and Therapeutics, and the American Society for Hematology. He serves on the Lymphoma and Pharmacology and Experimental Therapeutics (PET) Committees for the CALGB. He is a member of the Executive Committee for the Mantle Cell Lymphoma Consortium for the Lymphoma Research Foundation (LRF), and serves as a member of their Scientific Advisory Board. He is a Senior Editor for Clinical Cancer Research, and is also on the Editorial Board for the Journal of Clinical Oncology and Leukemia and Lymphoma. He has published nearly 100 articles in numerous journals, including Proceedings of the National Academy of Science, Journal of Clinical Oncology, British Journal of Hematology, Leukemia and Lymphoma, Clinical Cancer Research, Environmental Science and Technology and Environmental Toxicology and Chemistry. His research has resulted in numerous abstracts of papers presented at National and International meetings. Dr. O’Connor is the recipient of several honors and awards, including the Scholar in Clinical Research Award from the Leukemia and Lymphoma Society, a Merit Award from the American Society for Clinical Oncology, the William Guy Forbeck Scholar Award, and co-recipient of the Ellen Glesby Cohen Leadership Award from the LRF for his contributions to mantle cell lymphoma.
Roger Owen is a consultant haematologist and haematopathologist at Leeds Teaching Hospitals NHS Trust in the UK. His main research interests concern the diagnosis and disease monitoring in patients with WM, multiple myeloma and MGUS. He is a co-principal investigator of the WM1 trial of primary therapy in the UK and a member of the National Cancer Research Network indolent lymphoma clinical trials group. Dr. Owen is also responsible for the flow cytomteric based assessment of minimal residual disease in multiple myeloma trials in the UK.
Mathias J. Rummel, MD, PhD is the head of the Department for Hematology at the Clinic for Hematology and Medical Oncology at the Justus-Liebig University-Hospital, Gießen, Germany. Dr Rummel studied medicine at J.W. Goethe University Hospital in Frankfurt, Germany, obtaining his licence to practice medicine in 1995. Following this, he completed his doctoral degree and residency, obtained board certification in internal medicine, and was awarded his PhD from J.W. Goethe University Hospital.
Dr Rummel’s current research focuses on novel treatment approaches in hematological malignancies, most notably follicular and other indolent lymphomas as well as hairy cell leukemia and also ITP. He is the chair of the Study Group Indolent Lymphomas (StiL) and principal investigator of several on-going clinical protocols.
Dr Rummel is actively involved in a number of professional scientific societies, including the American Society of Hematology, American Society of Clinical Oncology, the European Society for Medical Oncology, the European Haematology Association, and the German Society of Haematology and Oncology. He is also a reviewer for a number of journals such as Haematologica, Annals of Oncology, Annals of Hematology, Leukemia and Lymphoma, and the Journal of Clinical Oncology. Dr Rummel is principal investigator of many clinical trials in leukaemia and lymphoma, and has published several book chapters and papers in peer-reviewed scientific journals.
Patricia Sheehy joined the Bing center in January of 2008, but has been a staff member of Dana-Farber Cancer Institute since 2000. Tricia worked as an infusion nurse and staff educator prior to becoming a Nurse Practitioner. She holds a Bachelor of Science degree in Nursing from the University of Pennsylvania and a Masters of Science degree in Nursing from the MGH Institute of Health Professions. Tricia has been an Oncology Certified Nurse since 2001. She is an active member of the National Oncology Nursing Society, and it’s Boston Chapter. Tricia’s primary focus is direct patient care.
Dr. Marvin J. Stone was born in Columbus, Ohio and grew up in nearby Bexley where he attended public schools. After completing premedical studies at Ohio State University (1955 to 1958), he attended the University of Chicago School of Medicine (1958 to 1963). Following his sophomore year in medical school, he took a year off to do research in the pathology department. In 1962, he received a master of science degree in pathology and, in 1963, the MD with Honors. He was inducted into Phi Beta Kappa, Alpha Omega Alpha, and Sigma Xi at Chicago. His internship and first-year residency were at Barnes Hospital in St. Louis on the ward medical service. From 1965 to 1968, he was a clinical associate in the Arthritis and Rheumatism Branch of the National Institute of Arthritis and Metabolic Diseases at the National Institutes of Health in Bethesda, Maryland. In 1968, he came to Dallas, Texas as a senior resident in medicine at Parkland Memorial Hospital, and the next year was a fellow in hematology/oncology.
Dr. Stone remained in Dallas on the faculty of The University of Texas Southwestern Medical School rising to the rank of associate professor with tenure. He moved to Baylor University Medical Center in 1976 to become the first chief of oncology and director of the new Charles A. Sammons Cancer Center, positions he held until 2008. He continued as a clinical professor in the Department of Internal Medicine at Southwestern Medical School after moving to Baylor.
Dr. Stone has served as program director of the Medical Oncology Fellowship at Baylor since 1984 and as head of the Junior Medical Student Clerkship since 1988. He has received Outstanding Teacher Awards from the Housestaff at Baylor and from Alpha Omega Alpha medical students at UT Southwestern. He is the author of over 200 articles and book chapters on various aspects of hematology-oncology, particularly monoclonal gammopathies. He also has a special interest in medical history. In 1999, Baylor Health Care System created the Marvin J. Stone Library at the Baylor Institute for Immunology Research. In 2001, Dr. Stone served as the Dr. Judah Folkman Scientist in Residence at Bexley High School and received the Wings of Eagles Award from Baylor Health Care System Foundation.
Dr. Stone is a Master of the American College of Physicians and was recognized with the Distinguished Service Award from the University of Chicago in 2002. He is a past president of the American Osler Society and was the first chair of the American Society of Clinical Oncology’s Career Development Committee. Dr. Stone was honored with the Lifetime Achievement Award in Waldenström’s Macroglobulinemia in 2004. In 2006, he contributed an invited essay on monoclonal antibodies to The Lancet’s Special Issue on Medicine and Creativity. Baylor’s Sammons Cancer Center and department of internal medicine sponsor the annual Marvin J. Stone Lectureship, which was established in 2009. Dr. Stone’s hobbies are collecting antique microscopes and historical medical books.
Dr. Steven Treon is the Director of the Bing Center for Waldenström’s Research and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenstrom's Macroglobulinemia Clinical Trials Group.
After earning a doctorate in tumor immunology from Boston University (BU), Dr Treon did a postgraduate fellowship in the Department of Microbiology at BU School of Medicine. Dr Treon received a medical degree from BU School of Medicine and completed an internship in medicine and a residency in internal medicine at BU Medical Center. Dr Treon also served a clinical fellowship in hematology and oncology at Mass General Hospital and a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine in 1995, and in medical oncology in 1997.
Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and the development of therapeutics for this malignancy. He serves on the editorial boards of the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. Dr Treon is a member of several professional societies including the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, European Society of Hematology and the Massachusetts Medical Society. He has been honored with several research and academic awards from various national and international medical foundations and institutes, including the Robert A. Kyle Award for Waldenstrom's Macroglobulinemia.